Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: inflammation, cardiovascular
- Who it enrolls
- age 50 Years to no upper limit; no BMI minimum stated; conditions: Type 2 Diabetes
- Interventions
- Semaglutide, 2.0 mg/mL
- Conditions
- Type 2 Diabetes
- Phase and size
- Phase 4 · 22 participants
- Dates
- Start 2023-01-01
Primary completion 2024-03 - Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Difference in coronary 68Ga-Dotatate uptake after treatment.6 months
02Eligibility
Who can take part
Inclusion Criteria: * Age \>50 years old * Diagnosed with type 2 diabetes * HbA1c \>64mmol/mol Exclusion Criteria: 1. (History of) malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator. 2. Chronic or recent infections and/or clinical signs of infection and/or a plasma C-reactive protein above 10ng/ml 3. Auto-immune diseases (including type 1 diabetes) 4. Recent or chronic immunosuppressant or antibiotic usage 5. Use of any GLP1R-agonist at baseline or prior intolerance to use of GLP1R-agonists. 6. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. 7. Uncontrolled hypertension (systolic blood pressure \> 180mmHg, diastolic blood pressure \> 100mmHg) 8. Uncontrolled chronic inflammatory conditions, including gout. 9. Women of childbearing age who are not using effective contraceptives. 10. Heart failure New York Heart Association (NYHA) class IV at screening visit. 11. Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) ≥ 2 times the upper limit of normal (ULN) at screening visit. 12. Pancreatitis in medical history.
03Change log
Registry changes
No changes recorded since the trial was added.